Monday, August 29, 2016

Cerecor Inc. Announces Initiation of Second CERC-501 Phase 2 Clinical Trial in Smokers

http://ift.tt/2clRM5k

“Does CERC-501 Attenuate Stress-Related Smoking Lapse?” The study is a collaborative effort between Cerecor and Dr. McKee and is supported by funding from the National Institutes of Health (NIH). “Stress is a primary contributor to the maintenance of, and

The post Cerecor Inc. Announces Initiation of Second CERC-501 Phase 2 Clinical Trial in Smokers appeared first on The Center.



Smoking Cessation Feeds

No comments:

Post a Comment